This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

An Open-Label Study of Amisulpride in the Treatment of Mania

Eduard Vieta, MD, PhD; Salvador Ros, MD; José Manuel Goikolea, MD; Antonio Benabarre, MD, PhD; Ekaterina Popova, MD; Mercè Comes, PSN; Jorge Capapey, MD; and José Sánchez-Moreno, PsyD

Published: May 15, 2005

Article Abstract

Background: Amisulpride is a selective D2-D3 antagonist that has been reported to be effective in the treatment of schizophrenia and major depressive disorder. However, no prospective study to date has assessed the effectiveness and tolerability of this compound in mania.

Method: Twenty DSM-IV-defined acutely ill manic bipolar patients with a Young Mania Rating Scale (YMRS) score of 20 or more entered this open, prospective, 6-week study. Assessments included the YMRS, the Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impressions Scale for Bipolar Disorder, Modified (CGI-BP-M), and the systematic report of adverse events. Amisulpride was added to other medications, but other antipsychotics were not allowed.

Results: Fourteen patients (70%) completed the study. Using last-observation-carried-forward (LOCF) analyses, amisulpride produced significant improvements on the YMRS (p = .0001), the HAM-D (p < .0141), and the overall (p = .0003), mania (p = .0001), and depression (p = .0268) subscales of the CGI-BP-M. The most common side effect was sedation (N = 5, 25%), but there were also some extrapyramidal symptoms, galactorrhea, insomnia, and agitation. The mean amisulpride dose was 680 mg/day (LOCF) and 786 mg/day in completers.

Conclusions: This first prospective study on amisulpride in the treatment of mania suggests that, despite the limitations of the open, observational design and small sample size, amisulpride may be effective and reasonably safe in the treatment of bipolar mania. D2 and D3 antagonism may be involved in the mechanisms of the therapeutic response to antipsychotics in mania.

Volume: 66

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF